In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
Data exclusivity is usually discussed in academic circles, mainly due to enforcement complexities and when cases are brought against the Federal Commission for the Protection against Sanitary Risks, the government branch in charge of issuing of marketing authorisations for drugs and agrichemicals.
However, data exclusivity protection is a crucial element for securing marketing exclusivity for both the pharmaceutical and agrichemical sectors, especially for orphan drugs and also for molecules the patent protection of which may be compromised in some manner, or simply unavailable.
For that reason, data exclusivity is a topic which appears regularly in the negotiation of bilateral and multilateral international treaties,including IP clauses, to which Mexico is a party.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Mexico, pharmaceutical, agrichemical, TPP, COFEPRIS, data exclusivity